👀 Ones to watch: Undervalued stocks to buy before they report Q3 earningsSee Undervalued Stocks

Novo Nordisk A/S Class B (NNO2)

Vienna
Currency in EUR
107.72
-1.92(-1.75%)
Closed
NNO2 Scorecard
Full Analysis
Has raised its dividend for 7 consecutive years
Unusual trading volume
Fair Value
Day's Range
107.68111.36
52 wk Range
87.25137.98
Bid/Ask
100.00 / 125.00
Prev. Close
109.64
Open
111.36
Day's Range
107.68-111.36
52 wk Range
87.25-137.98
Volume
973
Average Volume (3m)
365
1-Year Change
17.79%
Fair Value
Unlock
Fair Value Upside
Unlock
NNO2 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
945.80
Upside
+17.87%
Members' Sentiments
Bearish
Bullish
ProTips
5 analysts have revised their earnings downwards for the upcoming period
Show more

Novo Nordisk A/S Class B Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Employees
69260
Market
Denmark

Compare NNO2 to Peers and Sector

Metrics to compare
NNO2
Peers
Sector
Relationship
P/E Ratio
39.6x14.3x−0.6x
PEG Ratio
1.160.210.00
Price/Book
31.6x3.6x2.6x
Price / LTM Sales
13.8x3.2x3.2x
Upside (Analyst Target)
-4.8%49.1%
Fair Value Upside
Unlock10.5%7.2%Unlock

FAQ

What Is the Novo Nordisk B (NNO2) Stock Price Today?

The Novo Nordisk B stock price today is 107.72

What Stock Exchange Does Novo Nordisk B Trade On?

Novo Nordisk B is listed and trades on the Vienna stock exchange.

What Is the Stock Symbol for Novo Nordisk B?

The stock symbol for Novo Nordisk B is "NNO2."

Does Novo Nordisk B Pay Dividends? What’s The Current Dividend Yield?

The dividend yield is 1.23%.

What Is the Novo Nordisk B Market Cap?

As of today, Novo Nordisk B market cap is 476.66B.

What is Novo Nordisk B Earnings Per Share?

The Novo Nordisk B EPS is 20.14.

From a Technical Analysis Perspective, Is NNO2 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.